SAB Biotherapeutics announces research collaboration with CSL Behring

This article was originally published here

The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb platform. SAB has developed

The post SAB Biotherapeutics announces research collaboration with CSL Behring appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply